{{ variable.name }}
【Indications】
This product is an antisense oligonucleotide(ASO)targeting hepatitis B virus(HBV)mRNA.It is indicated for use in combination with a nucleos(t)ide reverse transcriptase inhibitor(NrtI)in non-cirrhotic adult patients with chronic HBV infection who meet all of the following criteria:
Receiving a stable NrtI regimen for at least 6 months,with HBV DNA<90 IU/mL;
Hepatitis B surface antigen(HBsAg)level≤3000 IU/mL.
【Recommended Dosage】
Weeks 1 and 2:
300 mg per administration,given as two 150 mg subcutaneous injections twice weekly,with 3 or 4 days between doses.
Week 3 through Week 24:
300 mg per administration,given as two 150 mg subcutaneous injections once weekly on the same day each week.
Notes:
This drug must not be used as monotherapy and shall be administered together with an NrtI throughout the treatment course.
The maximum recommended treatment duration is 24 weeks.If HBsAg remains≥1 IU/mL at Week 12,early discontinuation of this product may be considered.
Treatment with this product must be stopped upon completion of the 24-week course,and patients should continue NrtI therapy for at least 24 additional weeks.After this extra 24-week NrtI treatment,discontinuation of NrtI may be considered in patients who meet all of the following criteria:
Hepatitis B e antigen(HBeAg)negative;
HBV DNA<20 IU/mL,HBsAg undetectable(lower limit of detection LOD=0.05 IU/mL),and alanine aminotransferase(ALT)≤2 times the upper limit of normal(ULN);
No need for NrtI to manage co-infection with human immunodeficiency virus(HIV).
Following NrtI discontinuation,close monitoring of HBsAg,HBV DNA and liver function is recommended for at least 1 year;routine monitoring should be performed thereafter based on clinical needs.
【Adverse Reactions】
The most common adverse reactions(incidence≥10%)are injection site reactions,pyrexia,fatigue and headache.
【Pharmacology】
This is a synthetic single-stranded chimeric antisense oligonucleotide(ASO)with a gapmer architecture.It consists of two wings of five 2'-O-(2-methoxyethyl)(2'-MOE)-modified ribonucleotides flanking a central gap of ten deoxyribonucleotides,with a full phosphorothioate backbone.
The compound is designed to bind to a conserved 20-nucleotide region(nucleotides 1581–1600,5'-GCACTTCGCTTCACCTCTGC-3')present across all HBV mRNAs,including pregenomic RNA(pgRNA),precore,preS1,preS2/S and X mRNA.Binding forms a DNA:RNA heteroduplex that recruits endogenous ribonuclease H1(RNase H1)to catalyze irreversible hydrolysis of the viral RNA strand at the 3'-O-P bond,leading to HBV mRNA degradation and reduced HBV DNA and viral proteins including HBsAg.This binding site is present in transcripts from both cccDNA and integrated HBV DNA.
In transfection studies using HepG2.2.15 cells(HBV genotype D),the product reduced HBV RNA transcripts in a dose-dependent manner.Using two RT-qPCR primer/probe sets targeting pgRNA,preS1 and preS2/S mRNA,EC50 values were 70 nM(16 h)and 122 nM(48 h).
【Storage】
Store in a refrigerator at 2°C to 8°C.Do not freeze.Keep in the original carton to protect from light.Do not shake.
May be stored at room temperature below 30°C for up to 12 weeks.Do not freeze.Retain in the original carton,protected from light.Do not shake.Discard if past the expiry date or 12 weeks after receipt of the carton,whichever comes first.
Once removed from the carton,the injection must be administered within 6 hours.Discard if not used within 6 hours.